The FDA and Feasible Alternative Designs
Drug & Device Law
FEBRUARY 20, 2023
2003), aff’d , 810 N.Y.S.2d In at least the short term, a popular pain reliever would have to be removed from pharmacies. 7, 2022), which addressed the same question in the context of the admissibility of expert testimony. Therefore, Davis excluded as “not relevant” expert testimony about non-FDA-approved alternatives.
59 
Let's personalize your content